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Rabbits latently infected with herpes simplex virus type 1 (HSV-1) were vaccinated either periocularly or systemically with
a subunit vaccine (gB2 1 gD2) plus adjuvant or adjuvant alone. Tear films were collected daily to measure recurrent
infectious HSV-1 shedding. After systemic vaccination, the latently infected rabbits were not protected against recurrent
ocular viral shedding (HSV-1-positive tear film cultures/total cultures) compared with either the systemic or periocular
adjuvant controls (systemic vaccination 5 49 of 972, 5.0%; systemic control 5 46 of 972, 4.7%; periocular control 5 43 of 930,
4.6%; P . 0.8). In contrast, latently infected rabbits vaccinated periocularly with the same vaccine had significantly reduced
recurrent shedding (20 of 1026, 2.0%) compared with controls (P , 0.001) or systemic vaccination (P 5 0.0002). Thus,
recurrent HSV-1 shedding was significantly reduced by therapeutic local periocular subunit vaccination but not by thera-
peutic systemic subunit vaccination. Neutralizing antibody titers in the serum of systemically and ocularly vaccinated rabbits
was similar. In contrast, HSV-specific tear secretory immunoglobulin A was significantly higher in the ocularly vaccinated
group (P , 0.01). These results strongly suggest that in the rabbit, and presumably in humans, the local ocular (mucosal)
immune response is much more important than the systemic immune response for therapeutic protection against recurrent
ocular HSV-1. Thus development of a therapeutic vaccine against recurrent ocular HSV-1 should be directed at enhancing the
local ocular (mucosal) immune response. © 1998 Academic Press
Key Words: corneal disease; HSV-1; latency; recurrent disease; vaccine.
INTRODUCTION
Seventy to 90% of adults in the United States harbor
latent herpes simplex virus (HSV) infections. In addition
to producing genital and oral infections, HSV can infect
the eye. Approximately 90% of ocular HSV in humans is
due to HSV type 1 (HSV-1). After initial ocular infection,
HSV-1 establishes life-long latency in neurons of the
trigeminal ganglia. Spontaneous reactivations, in which
infectious virus returns to the eye and can be detected in
tear films, occurs sporadically throughout life, with or
without recurrent eye disease (herpetic keratitis). Once
HSV has recurred in the eye, corneal disease, stromal
scarring, and blindness can follow as the result of an
incompletely defined immune response to the virus
(Newell et al., 1989; Rouse et al., 1988). In the United
States, recurrent ocular HSV-1 infection is the leading
cause of corneal blindness due to an infectious agent
(Nesburn, 1974, 1983; Smith et al., 1980).
HSV-1 is usually acquired as a childhood infection.
Thus widespread prevention of primary ocular herpes by
prophylactic vaccination (i.e., a vaccine given to naive
individuals to prevent primary infection) would require
universal vaccination of infants and children and would
not help those with existing latent infection. In contrast, a
therapeutic vaccine (i.e., a vaccine given to latently in-
fected individuals to decrease or prevent recurrent infec-
tions) could be targeted at individuals who have experi-
enced primary ocular HSV-1 infection or who have a
history of HSV-1 ocular recurrences. In addition, elimina-
tion of recurrent ocular HSV-1 by eliminating primary
ocular HSV-1 via prophylactic vaccination would require
many decades because of the large pool of latently
infected individuals.
The development of therapeutic vaccines against vi-
ruses that normally produce multiple recurrent infections
is complicated. With these viruses, the immune response
to primary and recurrent infections is not sufficient to
eliminate subsequent recurrent infection. Thus a vaccine
that simply mimics the natural immune response is un-
likely to provide significant protection against recurrent
infection. A successful therapeutic HSV-1 vaccine may
therefore have to elicit an immune response that is either
much stronger than or different from that after natural
infection.
1 To whom reprint requests should be addressed at Room 5069,
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Vaccination before infection (i.e., prophylactic vaccina-
tion) can protect mice and rabbits against primary HSV-
1-induced corneal disease (Foster et al., 1988; Ghiasi et
al., 1995, 1996; Heiligenhaus et al., 1994, 1995; Inoue et
al., 1990; Irie et al., 1993; Keadle et al., 1997; Morrison
and Knipe, 1996; Nesburn et al., 1990). In mice, prophy-
lactic vaccination can decrease the rate of induced in
vivo reactivation (Keadle et al., 1997). Prophylactic vacci-
nation of mice and rabbits can also decrease the rate of
induced in vitro reactivation (Ghiasi et al., 1994, 1995,
1996; Nesburn et al., 1990). The decreased reactivation
rates were almost certainly a result of the prophylactic
vaccines providing some protection against primary oc-
ular challenge, thereby resulting in a decrease in the
amount of latency that was established (Ghiasi et al.,
1994, 1995, 1996; Nesburn et al., 1990). To obtain a
therapeutic vaccine effect, the vaccination must be given
to already infected individuals, not to naive individuals.
Using a rabbit model, we previously demonstrated a
vaccine and adjuvant combination that produces a ther-
apeutic reduction of spontaneous recurrent ocular HSV-1
shedding (Nesburn et al., 1994). Latently infected rabbits
were vaccinated via a local periocular route using highly
purified gD2 1 gB2 as antigen and MF59 (microfluidized
formulation #59 emulsion)–MTP-PE (N-acetyl-muramyl-
l-alanyl-d-isoglutaminyl-l-alanine-2–1,2-dipalmitoyl-sn-
glycero-3-(hydroxyphosoryloxy)ethylamide) as adjuvant.
This therapeutic vaccination resulted in a 2- to 3-fold
decrease in spontaneously reactivated HSV-1 in tear
films. We also recently showed that it is even easier to
protect against recurrent herpetic corneal disease than
against recurrent virus shedding (Nesburn et al., 1998a).
Vaccine efficacy lasted longer against herpetic keratitis
than against recurrent spontaneous shedding. In addi-
tion, homotypic vaccination was much more efficacious
than heterotypic vaccination against recurrent HSV-1
shedding, whereas heterotypic and homotypic vaccina-
tions were equally efficacious against recurrent herpetic
keratitis. Because the ability of a therapeutic vaccine to
reduce recurrent shedding appears to be a more strin-
gent measure of vaccine efficacy than the ability to de-
crease corneal disease and because measuring recur-
rent shedding is much more objective than measuring
corneal disease, in this report we used decreased recur-
rent viral shedding as the end point for therapeutic vac-
cine efficacy against ocular herpes recurrence.
We performed a number of studies in which rabbits
latently infected with HSV-1 were vaccinated with a va-
riety of vaccine preparations to look for therapeutic vac-
cine efficacy against recurrent ocular shedding, recur-
rent corneal disease, or both. In some studies, candidate
therapeutic vaccines were delivered systemically (intra-
muscularly or subcutaneously). In other studies, candi-
date therapeutic vaccines were delivered periocularly
(subconjunctival injection or topical application to the
cornea). Some, but not all, of the vaccines delivered
periocularly were efficacious against spontaneous shed-
ding (Nesburn et al., 1994) and recurrent corneal disease
(Nesburn et al., 1998a). In contrast, none of the vaccines
delivered systemically provided significant reductions in
recurrent shedding or disease (unpublished results). Al-
though none of the systemic vaccination studies were
done with vaccines that provided protection when deliv-
ered periocularly, these findings nevertheless led to the
hypothesis that periocular therapeutic vaccine delivery
may be more efficacious against recurrent HSV-1 than
systemic delivery. Testing this theory is the focus of this
report.
We report here that in cohorts of rabbits latently in-
fected with HSV-1 and vaccinated either periocularly or
systemically with the same vaccine preparation, the peri-
ocular vaccine had a vaccine efficacy during the 27-day
TABLE 1
Vaccines
Vaccinea Route Inocula No. of rabbits
Ocular gB2 1 gD2
(periocular vaccine)
Subconjunctivalb 7.5 mg of gB2,d 7.5 mg of gD2,d
MF59 1 MTP-PE
19
Systemic gB2 1 gD2
(systemic vaccine)
Intramuscularc 25 mg gB2,e 25 mg gD2,e MF59
1 MTP-PE
18
Ocular control (periocular
mock vaccine)
Subconjunctivalb PBS, MF59 1 MTP-PE 17–18f
Systemic control (systemic
mock vaccine)
Intramuscularc PBS, MF59 1 MTP-PE 18
a All vaccines were administered three times at 3-week intervals. The first vaccination was given 3 weeks after initial ocular infection, at which time
all rabbits harbored bilateral latent infections of the trigeminal ganglia.
b 0.1 ml per eye.
c 0.1 ml per rabbit.
d Per eye, 15 mg of each protein per rabbit.
e Per rabbit.
f Study began with 18 rabbits. One rabbit died after tear collection on day 5.
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monitoring period of 57% (as measured by decreased
spontaneous ocular shedding of HSV-1), whereas the
systemic vaccine showed no vaccine efficacy.
RESULTS
Ocular vaccination of rabbits with preexisting HSV-1
latent infection
To establish cohorts of rabbits with HSV-1 bilateral
latent infections of the trigeminal ganglia, rabbits were
infected in both eyes with HSV-1 strain McKrae as de-
scribed under Materials and Methods. Twenty-eight days
p.i., the surviving latently infected rabbits were divided
into four groups. As described under Materials and
Methods and Table 1, the rabbits in the periocular vac-
cine group were vaccinated subconjunctivally with gB2
1 gD2/MF59–MTP-PE, whereas the rabbits in the peri-
ocular mock vaccine group were vaccinated with the
adjuvant MF59–MTP-PE alone. The systemic vaccine
and the systemic mock vaccine groups were vaccinated
intramuscularly with the same vaccines. Three vaccina-
tions were given at 3-week intervals.
Recurrent viral shedding in tears during the initial 27-
day monitoring period
Beginning 3 weeks after the final vaccination, tear
films were collected daily from all eyes and individually
plated on indicator cells to assay for the presence of
reactivated (recurrent) virus. The cumulative number of
positive cultures during the 27 days of collection is
shown in Fig. 1. The data were standardized to represent
cumulative positive cultures per eye. The periocular
mock-vaccinated control group, the systemic mock-vac-
cinated control group, and the systemic vaccine group
each had an average of 1.26–1.36 positive cultures per
eye for the observation period. In contrast, the periocular
gB2 1 gD2/MF59–MTP-PE-vaccinated rabbits had, on
average, only 0.53-positive cultures per eye.
A statistical analysis of positive versus total tear film
cultures is shown in Table 2. During the 27-day monitor-
ing period, only 2.0% of the tear films from rabbits vac-
cinated periocularly with gB2 1 gD2 plus adjuvant were
positive for virus compared with 4.6% of the tear films
from rabbits mock-vaccinated periocularly. This differ-
ence was significant (Table 2, column 3; P 5 0.0008, x2).
In contrast, 5.0% of the tear films from rabbits vaccinated
systemically with the same gB2 1 gD2 plus adjuvant
vaccine contained recurrent virus, which was similar to
the 4.7% of positive tear films in the systemic mock-
vaccinated group (P 5 0.83). Thus compared with its
control, periocular vaccination provided protection
against recurrent ocular shedding, whereas compared
with its control, systemic vaccination did not. A direct
comparison of periocular gB2 1 gD2 plus adjuvant vac-
cination with systemic gB2 1 gD2 plus adjuvant vacci-
nation indicated that the periocular vaccination was
much more efficacious at reducing spontaneous recur-
rent shedding (P 5 0.0002). The vaccine efficacy of the
periocular gB2 1 gD2 plus adjuvant vaccine calculated
as described under Materials and Methods was 57%
compared with no vaccine efficacy for the same vaccine
delivered systemically (Table 2, column 5).
The above analyses are commonly used for the eval-
uation of these types of experiments. However, these
approaches do not take into account the number of eyes
in each group and therefore do not distinguish among (1)
large numbers of eyes observed over a short period of
time, (2) moderate numbers of eyes over a moderate
time, or (3) small numbers of eyes over a long period of
time. Therefore, we also analyzed the data by another
approach. For each eye in each group, the fraction of
virus-positive days was determined (total virus-positive
FIG. 1. Effect of therapeutic local vaccination versus therapeutic
systemic vaccination on HSV-1 spontaneous ocular shedding over a
27-day monitoring period. Rabbits were ocularly infected with HSV-1
McKrae as described under Materials and Methods. Once latency had
been established, groups of rabbits were vaccinated either periocularly
(subconjunctivally) or systemically (intramuscularly on the back) with
gB2 1 gD2/MF59–MTP-PE or mock vaccinated with the adjuvant alone
(control) as described under Materials and Methods. Identical vacci-
nations were given 21 and 42 days later for a total of three vaccinations.
Beginning 21 days after the final vaccination, tear films were collected
daily from all eyes as described under Materials and Methods. The
cumulative number of HSV-1-positive cultures for each group, divided
by the number of eyes in that group, are shown. Ocular vac indicates
periocular subconjunctival vaccination; systemic vac, systemic intra-
muscular vaccination; ocular con, control periocular subconjunctival
vaccination; systemic con, control systemic intramuscular vaccination.
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tear film cultures/total tear film cultures for each individ-
ual eye). The resulting fractions (one for each eye) then
were subjected to statistical analysis (Mann–Whitney
rank sum tests). Because each eye is now represented
by the fraction of virus-positive days, this analysis takes
into account the number of eyes in each group. By this
more stringent analysis, periocular vaccination with gB2
1 gD2 was also more efficacious in decreasing recur-
rent shedding than systemic vaccination with the same
material (Table 2, column 3; P 5 0.004). The decrease in
recurrent shedding for the group vaccinated periocularly
with gB2 1 gD2 approached significance compared with
the mock-vaccinated periocular control using a two-
sided analysis (P 5 0.06; Table 2; column 4) and reached
significance using a one-sided analysis (P 5 0.03, not
shown). Finally, systemic vaccination did not decrease
recurrent shedding compared with its control (P 5 0.31).
Thus during the 27-day monitoring period, periocular
vaccination with gB2 1 gD2 was efficacious compared
with its control and compared with systemic vaccination
with the same vaccine, whereas systemic vaccination
was not efficacious compared with its control.
Recurrent viral shedding in tears during an extended
47-day monitoring period
To examine longer-term therapeutic protection against
recurrent ocular shedding, the monitoring period for the
periocular gB2 1 gD2 vaccine group and its periocular
mock vaccine control was extended to a total of 47 days
(Fig. 2). During this longer period, the periocular gB2 1
gD2 vaccine group had an average of 1.3 positive tear
TABLE 2
Recurrent Ocular HSV-1 Shedding Days 1–27
Positive/total eye
culturesa
P
(less stringent)b
P
(more stringent)c Vaccine efficacyd
Ocular gB 1 gD 20/1026 (2.0%) 57%
Systemic gB 1 gD 49/972 (5.0%) 0%
Ocular adj 43/930 (4.6%)
Systemic adj 46/972 (4.7%)
Ocular gB 1 gD vs
ocular control
0.0008 0.06
Systemic gB 1 gD vs
systemic control
0.83 0.31
Ocular gB 1 gD vs
systemic gB 1 gD
0.0002 0.004
Ocular gB 1 gD vs
systemic control
0.14
Systemic gB 1 gD vs
ocular control
0.48
a Tears were collected daily from all eyes for 27 days and cultured on indicator cells for the presence of reactivated HSV-1. The number of
HSV-1-positive cultures/total number of cultures is shown for each group of rabbits.
b Chi-squared test (two-sided) based on total number of positive and negative cultures in each group.
c The fraction of time each eye was positive for recurrent HSV-1 (number of positive tear film cultures/total number of cultures) was determined,
producing a fraction for each eye. The sets of fractions were compared using the Mann-Whitney rank sum test (two-sided).
d Vaccine efficacy was determined as described under Materials and Methods.
FIG. 2. Effect of vaccination on recurrent HSV-1 shedding over an
extended 47-day monitoring period. Tears were collected daily from the
ocular vaccinated and control groups for an additional 20 days and
assayed, and the results are plotted as described in the legend to
Fig. 1.
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film cultures per eye compared with an average in the
periocular mock vaccine control group of almost twice
this number or ;2.5-positive cultures per eye. Further-
more, 5.2% of the tear films contained spontaneously
reactivated virus in the control group compared with only
2.7% in the gB2 1 gD2 vaccine group (Table 3). This
difference was significant even by the more stringent
statistical analysis (Table 3; column 4). The vaccine effi-
cacy over the entire 47-day monitoring period was 48%
(Table 3). This was slightly lower than the 57% vaccine
efficacy during the first 27 days, suggesting that there
was a small decrease in therapeutic vaccine efficacy
between days 28 and 47 of the monitoring period corre-
sponding to days 49 to 68 after the final vaccination. This
was confirmed by analysis of just the last 20 days of the
47-day extended monitoring period (days 28–47) rather
than the entire 47-day period. The reduction in the per-
cent of tear films that contained spontaneously reacti-
vated virus in the gB2 1 gD2 periocular vaccine group
(3.8%) compared with the mock vaccine group (6.0%)
approached but did not reach significance, even using
the less stringent analysis (P 5 0.06, not shown).
Vaccination-induced neutralization titers
Sera were obtained from five rabbits in each vaccina-
tion group 3 weeks after the initial infection (just before
the first vaccination) or 3 weeks after the final vaccina-
tion. Anti-HSV-1 serum neutralization titers were deter-
mined on individual sera as described under Materials
and Methods. Before vaccination, four of five sera in
each group had neutralization titers of ,50 (the base
level of the assay) (Table 4; p.i.–prevaccination). After the
final vaccination, the systemic gB2 1 gD2 vaccine group
had a mean neutralization titer of 291 6 52 and the
periocular gB2 1 gD2 vaccine group had a mean titer of
243 6 28 (Table 4; postvaccination). These postvaccina-
tion titers were significantly higher than the prevaccina-
tion titers (P , 0.008, Mann–Whitney test). Because in
previous studies we showed that mock vaccination with
the same adjuvant used here does not alter serum neu-
tralization titers (Nesburn et al., 1994, 1998a), these re-
sults indicated that the rabbits developed an immune
response after both systemic and periocular vaccina-
tions. There was no significant difference between the
TABLE 3
Recurrent Ocular HSV-1 Shedding Days 1–47
Positive/total eye
culturesa
P
(less stringent)
P
(more stringent) Vaccine efficacy
Ocular gB 1 gD 49/1786 (2.7%) 0.0002 0.02 48%
Ocular control 84/1610 (5.2%)
a Tears were collected daily from all eyes for 47 days and cultured on indicator cells for the presence of reactivated HSV-1. Analyses are as
described for Table 1.
TABLE 4
Effect of Vaccination on Serum HSV-1 Neutralizing Antibody Titers
Neutralizing antibody titersa
Ocular vaccination Systemic vaccination
Postinfection
(prevaccination) Postvaccination
Postinfection
(prevaccination) Postvaccination
,50 222 ,50 400
,50 163 ,50 250
,50 300 ,50 375
,50 314 ,50 111
64 217 80 320
Mean 6 SEMb 53 6 3 243 6 28 56 6 6 291 6 52
P, postinfection vs postvaccinationb 0.008 0.008
P, ocular vs systemic postvaccinationc 0.31
a Sera were collected 3 weeks p.i. just before the first vaccination (postinfection-prevaccination) or 3 weeks after the final vaccination (postvac-
cination), corresponding to 12 weeks p.i. Serum neutralization titers were determined on individual sera from five randomly selected rabbits/group
p.i. and five randomly selected rabbits/group postvaccination as described under Materials and Methods.
b For statistical analysis, 50 was substituted for ,50, Mann-Whitney test.
c Mann-Whitney test.
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postvaccination HSV-1 neutralization titers of the sys-
temic and periocular vaccination groups (P 5 0.31). Thus
the higher vaccine efficacy of the periocular vaccination
was not due to induction of a higher serum neutralization
titer.
Vaccination induced anti-HSV-1 tear secretory
immunoglobulin A
Tears were collected 3 weeks after the final therapeu-
tic vaccination. Anti-HSV-1 secretory immunoglobulin A
(sIgA) in individual tear samples was evaluated as de-
scribed under Materials and Methods using purified gD2
as the capture antigen (Fig. 3A). The average anti-gD tear
sIgA titer was significantly greater in the ocular vaccine
group than in the systemic vaccine group (P , 0.01). Both
the ocular and systemic vaccine groups had higher gD-
specific tear sIgA than the mock vaccine groups (P ,
0.01). Similar results were obtained using gB2 as the
capture antigen (Fig. 3B), but the difference between the
ocular and systemic vaccines did not reach statistical
significance (P 5 0.14, Student’s t test). Taken together,
these results indicate a correlation between therapeutic
subunit vaccine efficacy against HSV-1 ocular recur-
rence and induction of anti-HSV tear sIgA.
DISCUSSION
We previously reported that subunit therapeutic local
periocular vaccination of rabbits harboring bilateral la-
tent infections in both trigeminal ganglia was able to
reduce recurrent HSV-1 ocular shedding (Nesburn et al.,
1994, 1998a). However, the requirement for periocular
delivery compared with systemic delivery to achieve this
therapeutic efficacy had not been determined. Prophy-
lactic vaccine efficacy against primary ocular challenge
with HSV-1 has been obtained in the rabbit by systemic
vaccination (a prophylactic vaccine in contrast to the
therapeutic vaccine used in this study) (Nesburn et al.,
1990). Recently, however, we demonstrated that perioc-
ular vaccination provided more efficacious protection
against primary ocular HSV-1 challenge in the rabbit than
does systemic vaccination (Nesburn et al., 1998b). Based
on this finding, it appeared likely that periocular vacci-
nation also would be more efficacious for therapeutic
protection. However, because the immune responses
involved in prophylactic protection may differ from those
involved in therapeutic protection, this assumption re-
quired experimental confirmation as reported here. The
adjuvant MTP-PE, used in the above studies and in the
studies reported here, was selected because at the time
these studies started, it appeared that MTP-PE was likely
to be approved for human use. Unfortunately, unaccept-
able local side effects occurred with MTP-PE in human
studies, and it is no longer considered to be a candidate
for human use.
In the studies reported here, therapeutic local perioc-
ular vaccination with gB2 1 gD2/MF59–MTP-PE resulted
in a vaccine efficacy against spontaneous recurrent oc-
ular virus shedding of 57% during a 27-day monitoring
period. In contrast, systemic vaccination with the same
vaccine resulted in no measurable vaccine efficacy. The
protection afforded by periocular delivery is even more
impressive because to strengthen the likelihood that any
increased protection observed with ocular vaccination
would be meaningful, the vaccinations were biased to-
ward systemic vaccinations. Thus a lower dose of gB2 1
FIG. 3. Effect of therapeutic vaccination on HSV-specific tear sIgA.
Tears were collected 3 weeks after the final vaccination and were
individually assayed for HSV-specific sIgA by ELISA using gD2 (A) or
gB2 (B) as the capture antigen as described under Materials and
Methods. (A) Ocular vaccine: average of sIgA titers from 12 eyes;
systemic vaccine: 12 eyes; ocular mock: 4 eyes; systemic mock: 2 eyes.
(B) Ocular vaccine: 6 eyes; systemic vaccine: 11 eyes; ocular mock: 2
eyes; systemic mock: 1 eye.
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gD2 was used periocularly (7.5 mg/eye of each glyco-
protein versus 25 mg of each glycoprotein given system-
ically). Because subconjunctival (periocular) vaccination
should induce much stronger mucosal immune re-
sponses at the eye than systemic vaccination, one ex-
planation for the effectiveness of therapeutic periocular
vaccination compared with systemic therapeutic vacci-
nation is that induction of mucosal immune responses
was required for therapeutic vaccine efficacy against
ocular HSV-1 recurrences in this system.
Interestingly, although greater vaccine efficacy against
recurrent shedding was achieved via the ocular route
than by the systemic route, the average serum neutral-
ization titers induced by the two different vaccine routes
were similar. Thus therapeutic vaccine efficacy did not
correlate with the induction of increased serum neutral-
izing antibody by the efficacious vaccine. In this study,
using a subunit vaccine, the ability of vaccination to
induce serum neutralization titers therefore was not pre-
dictive of vaccine efficacy against recurrent ocular shed-
ding of spontaneously reactivated virus. In contrast to the
serum neutralizing antibody titers, therapeutic protection
against recurrent HSV-1 ocular shedding correlated with
HSV-specific tear sIgA when groups were examined as a
whole. However, there did not appear to be a strong
correlation between sIgA and protection for specific eyes
or rabbits (analysis not shown). Nevertheless, these re-
sults support the notion that for therapeutic efficacy
against recurrent HSV-1 in the eye, local mucosal immu-
nity is more important than systemic humoral immunity.
Mucosal immunity (or secretory immunity) is the first
line of defense for protecting mucosal surfaces, includ-
ing the eye, against microbial invasion. The major pro-
tective action of mucosal immunity is mediated by sIgA
(Sullivan, 1994), which is the main immunoglobulin in
tears. sIgA can inhibit the attachment and internalization
of viruses (Malaty et al., 1988) and therefore is likely to be
important in protection against ocular HSV-1 infection.
The lacrimal gland is the main source of tears and tear
sIgA. The conjunctiva contains T, B, and plasma cells
expressing IgA and may also be involved in ocular mu-
cosal immunity (Sullivan, 1994).
Mucosal immunity is distinct from systemic immunity.
Vaccination at mucosal sites often induces systemic, as
well as mucosal, immune responses. In contrast, sys-
temic vaccination rarely induces significant mucosal im-
munity (Sullivan, 1994). Thus for a vaccine to induce
significant mucosal immune responses, it usually has to
be delivered mucosally. In human studies of a prophy-
lactic HSV vaccine, systemic vaccination with gB2 1
gD2-induced high serum neutralization titers in HSV-
seropositive persons (6- to 13-fold higher than natural
infection after vaccination of latently infected individuals)
(Straus et al., 1993, 1994), yet it produced no significant
vaccine efficacy against primary or recurrent genital her-
pes (R. L. Burke, personal communication). More re-
cently, a similar vaccine also induced high serum neu-
tralization titers without decreasing the rate of genital
herpes recurrences during a 1-year period (Straus et al.,
1997). These studies may suggest the importance of
local/mucosal immunity rather than systemic immunity in
protecting against recurrent herpes simplex virus.
The results seen here in the rabbit ocular model of
HSV-1 spontaneous reactivation differ from that recently
reported in the mouse ocular model of UV-induced reac-
tivation (Walker et al., 1998). We showed here that in
rabbits, therapeutic ocular vaccination, but not therapeu-
tic systemic vaccination, significantly reduced the
amount of spontaneous recurrent shedding, strongly
suggesting that vaccine efficacy against recurrent ocular
shedding required induction of local/mucosal immunity.
In contrast, in mice, therapeutic intraperitoneal vaccina-
tion was able to decrease induced recurrent ocular
shedding. These difference could be due to the use of a
subunit vaccine in the rabbit compared with an attenu-
ated live virus vaccine in the mouse or the use of spon-
taneous reactivation in the rabbit compared with induced
reactivation in the mouse. More likely, however, these
results suggest either less ocular mucosal surface im-
mune privilege in the mouse or that in the mouse ther-
apeutic ocular protection can be achieved by immune
responses that do not protect rabbit eyes. In addition, in
mice, therapeutic ocular vaccine efficacy correlated well
with induction of high serum neutralizing antibody titers
(Walker et al., 1998). In contrast, in the current study,
serum neutralizing antibody titers did not correlate with
therapeutic ocular vaccine efficacy in the rabbit. In hu-
mans, serum neutralizing antibody titers also do not
correlate with protection against recurrent ocular HSV-1
because individuals with continuing recurrent disease
can develop extremely high serum neutralizing antibody
titers while remaining susceptible to continuing recur-
rences.
The ability of the mouse and the inability of the rabbit
to be protected against recurrent ocular HSV-1 by sys-
temic immunity have also been seen for vaccine protec-
tion against primary ocular infection. In the mouse, sys-
temic immunization (Ghiasi et al., 1992, 1995) and even
intraperitoneal injection of neutralizing antibody (Walker
et al., 1998) can protect against ocular HSV-1 challenge.
In contrast, we recently showed that in rabbits, periocu-
lar vaccination with either subunit or live virus vaccines,
was much more efficacious than systemic vaccination in
protecting against ocular HSV-1 challenge (Nesburn et
al., 1998b).
We theorize that the ability of serum antibody to pro-
tect the mouse, but not the rabbit or human eye, may be
due to eye size. In rabbits and humans, capillaries are
only seen in the outer 1 mm of the cornea, effectively
isolating the central cornea from circulating immune fac-
tors. In the mouse, capillaries are also confined to the
outer 1 mm of the cornea. However, because of the small
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size of the mouse cornea compared with rabbits and
humans, it is likely that circulating immune factors can
rapidly diffuse from these peripheral capillaries into the
central cornea, thus allowing serum antibody to protect
the mouse cornea. The ability of nonmucosal immunity
(i.e., serum antibody) to protect the mouse eye may
complicate deciphering the role of mucosal immunity in
protection against recurrent ocular HSV-1, thereby result-
ing in an underestimation of the importance of vaccine-
induced local/mucosal immunity in humans. Thus al-
though rabbit immunology still lags behind that of the
mouse, the rabbit is an important model for studying
vaccine efficacy against ocular HSV-1 as it may apply to
humans.
Whether therapeutic efficacy in the rabbit ocular
model can also be achieved with a live virus vaccine and,
if so, whether as seen here for a subunit vaccine, an
ocular vaccine route would be more efficacious than a
systemic vaccine route remains to be determined. Re-
gardless, the results reported here suggest that thera-
peutic vaccine efficacy in the rabbit model of ocular
HSV-1 spontaneous reactivation was due to mucosal
rather than systemic immunity because (1) therapeutic
vaccine efficacy was achieved with periocular (subcon-
junctival) vaccination, but not by systemic vaccination,
even with a larger dose of the same vaccine; and (2)
therapeutic efficacy correlated with induction of HSV-
specific tear sIgA but not with induction of serum HSV-1
neutralizing antibody titers. Studies are planned to de-
termine whether other mucosal routes of vaccination,
such as intranasal or enteric, may prove equally effica-
cious as ocular vaccination and to determine whether
other local ocular mucosal immune responses in addi-
tion to sIgA correlate with therapeutic vaccine efficacy.
MATERIALS AND METHODS
Virus
The HSV-1 strain McKrae was used for all experi-
ments. The virus was triple plaque purified and pas-
saged twice in CV-1 cells to produce a virus stock with a
titer of 2 3 108 pfu/ml.
Rabbits
New Zealand White male rabbits (Irish Farms) were
8–10 weeks old at the start of the procedure. Rabbits
were treated in accordance with Association for Re-
search in Vision and Ophthalmology (ARVO), American
Association for Laboratory Animal Care (AALAC), and
National Institutes of Health (NIH) guidelines.
Rabbit model of ocular HSV-1 infection, latency, and
spontaneous reactivation
To establish a cohort of rabbits with spontaneous
recurrent ocular HSV-1 infections, naive rabbits were
bilaterally infected without scarification or anesthesia by
placing 2 3 105 pfu (HSV-1 strain McKrae) in a total
volume of 50 ml into the conjunctival cul-de-sac, closing
the eye, and rubbing the lid gently against the eye. As we
have previously described, by day 21 p.i., all trigeminal
ganglia in the surviving rabbits harbor a latent HSV-1
infection, resulting in a high group rate of spontaneous
reactivation (;5–10% of tear film cultures are positive for
HSV-1 on any given day) (Nesburn et al., 1994; Perng et
al., 1994, 1996a, 1996b). Acute ocular infection was con-
firmed by HSV-1-positive tear film cultures collected on
days 3–4 p.i. To control for a possible bias introduced by
the severity of the initial infection, the latently infected
rabbits were divided into four similar groups based on
the severity of corneal disease observed during the
acute phase of HSV-1 infection. Thus each group con-
tained rabbits with a similar spectrum of acute eye dis-
ease severity. The resulting groups then were randomly
assigned to receive one of the four vaccine treatments:
(1) periocular gB2 1 gD2 plus adjuvant, (2) systemic gB2
1 gD2 plus adjuvant, (3) periocular adjuvant alone, or (4)
systemic adjuvant alone.
Glycoproteins for vaccination
HSV-2 glycoproteins D (gD2) and B (gB2) were pre-
pared by expression of the carboxyl-terminal truncated
gene in Chinese hamster ovary cells followed by purifi-
cation to near-homogeneity using a series of traditional
chromatographic steps as previously described and as
previously used by Chiron Corporation in clinical trials
measuring protection from HSV-2 infection (Langenberg
et al., 1995). gD2 is a carboxyl-terminal truncation com-
posed of amino acids 1–294 with three additional non-
gD2 amino acids, Leu-Thr-Asn, at the carboxyl-terminus.
The entire extracellular domain composes amino acids
1–313. gB2 is a transmembrane deletion composed of
amino acids 1–702 (the entire extracellular domain),
fused at the carboxyl-terminus to amino acids 777–882
(the entire cytoplasmic domain). Both HSV-2 genes were
obtained from strain 333.
Adjuvant and vaccine preparation
The adjuvant MF59 with MTP-PE was prepared as
follows. MF59 contained 5% (v/v) squalene (E. Merck,
Germany) a natural metabolizable oil, and 0.5% (v/v) each
of the surfactants Tween 80 (polyoxyethylene sorbitan
mono-oleate) and Span 85 (sorbitan trioleate) (ICI Amer-
ica, DE). The mixture was emulsified by mixing at high
pressure (;10,000 lb/in2) using a Microfluidics emulsifier
(Model 110Y, Newton, MA). The resulting emulsion was
sterile filtered and stored at 4°C. MTP-PE obtained as a
dry powder from Ciba-Geigy (Basle, Switzerland) was
dissolved in the aqueous phase of the emulsion mixture
before homogenization. This adjuvant was previously
used in human clinical trials against genital herpes (Lan-
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genberg et al., 1995). The vaccine, containing MF59 with
50 mg of MTP-PE per dose (MF59–MTP-PE), was pre-
pared just before immunization by mixing 1 volume of a
mix of gB2 and gD2 in 23 PBS with 1 volume of emul-
sion.
Systemic vaccination
All rabbits received three inoculations at 3-week inter-
vals. Each inoculation with gB2 1 gD2/MF59–MTP-PE
was delivered by a single intramuscular injection on one
side of the lower back. Each dose contained 25 mg of
each glycoprotein (gB2, gD2) in a total volume of 0.1 ml.
Control, mock-vaccinated rabbits were inoculated iden-
tically and on the same schedule. The control vaccine
consisted of MF59–MTP-PE plus PBS and was prepared
as described above except that the 23 PBS contained no
glycoproteins. The control vaccine contained the adju-
vant alone without glycoproteins.
Periocular vaccination
Before inoculation, the rabbits were anesthetized with
an intramuscular injection of ketamine/xylazine, and 1–2
drops of a 1% solution of proparacaine was applied
topically, as eye drops, for local anesthesia. The vaccine
was delivered by subconjunctival inoculation in the up-
per cul-de-sac using a 30-gauge needle and a dispos-
able insulin syringe. Each eye received three inocula-
tions of gB2 1 gD2/MF59–MTP-PE at 3-week intervals.
Each vaccine dose contained 7.5 mg of each glycoprotein
in a final volume of 0.1 ml. Vaccination resulted in ;25%
of the eyes showing mild-to-moderate conjunctival and
eye lid inflammation for up to 7 days.
Tissue culture assay for HSV-1 ocular shedding
As previously described (Nesburn et al., 1994), begin-
ning 3 weeks after the final vaccination, tear film speci-
mens were collected daily from each eye using a nylon-
tipped swab. The swab was placed in 0.5 ml of tissue
culture medium containing antibiotics and antifungal
agents, and the inoculated medium was used to infect
rabbit skin (RS) cell monolayers. Cell monolayers were
observed in a masked fashion by phase contrast micros-
copy for HSV-1 cytopathic effects. Positive cultures were
blind passaged onto fresh RS cells for confirmation.
HSV-1 serum neutralization assay
Neutralizing antibody titers were done by 50% plaque
reduction assays on CV-1 cells as described previously
(Nesburn et al., 1990).
ELISA assays for tear sIgA
Tears were collected with a microcapillary pipet and
ELISAs were performed as previously reported (Mertz et
al., 1990) using either gD2 or gB2 as the capture antigen,
goat anti-rabbit sIgA (Cappel, West Chester, PA) as the
primary antibody, and anti-goat IgG alkaline phospha-
tase as the secondary antibody (Cappel).
Percent vaccine efficacy
Vaccine efficacy was calculated as 1 minus (the frac-
tion of virus-positive tear films in the vaccine group,
divided by the fraction of virus-positive tear films in the
control group). This number then was multiplied by 100%
to obtain the percent vaccine efficacy.
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